IP Library › Granted Patent US 10,772,882
Granted Patent B2
US 10,772,882 · App. 16/310,209 · Granted Sep 15, 2020

Pulmonary hypertension preventative or therapeutic agent containing crude drug

Inventors: Hiroaki Shimokawa (Miyagi, JP); Hidetoshi Tokuyama (Miyagi, JP); Hirofumi Ueda (Miyagi, JP); Jyunken Aoki (Miyagi, JP); Takayuki Doi (Miyagi, JP); Kuniyuki Kano (Miyagi, JP); Kimio Satoh (Miyagi, JP); Ryo Kurosawa (Miyagi, JP)
Assignee: TOHOKU UNIVERSITY
A61K31/4745A61P9/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,772,882
App. No.
16/310,209
Granted
Sep 15, 2020
Kind
B2
Abstract

A problem to be solved by the present invention is to provide a novel preventive or therapeutic agent for pulmonary hypertension containing as an active ingredient a compound that has not been known for a therapeutic effect on pulmonary hypertension heretofore. The present invention provides a preventive or therapeutic agent for pulmonary hypertension containing emetine or a salt thereof.

Claims (8)

1. A method of treating pulmonary hypertension, comprising administering to a subject in need thereof an effective dose of emetine or a salt thereof.

2. The method according to claim 1 , wherein a daily dose of the preventive or therapeutic agent for pulmonary hypertension is 8 mg or less in terms of dose of emetine.

3. The method according to claim 1 , wherein pulmonary hypertension is pulmonary arterial hypertension.

4. The method according to claim 2 , wherein pulmonary hypertension is pulmonary arterial hypertension.

5. The method according to claim 1 , wherein emetine or a salt is orally administered.

6. The method according to claim 2 , wherein emetine or a salt is orally administered.

7. The method according to claim 3 , wherein emetine or a salt is orally administered.

8. The method according to claim 4 , wherein emetine or a salt is orally administered.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: SHIMOKAWA, HIROAKI; TOKUYAMA, HIDETOSHI; UEDA, HIROFUMI; AOKI, JYUNKEN; DOI, TAKAYUKI; KANO, KUNIYUKI; SATOH, KIMIO; KUROSAWA, RYO
To: TOHOKU UNIVERSITY
Reel/Frame 047782/0386 →
Priority Claims (1)
JP 2016-120901 · Jun 17, 2016 · national
Continuity (1)
Related Publication 20190321354A1 · Oct 24, 2019